1 / 21

Contexte de la recherche ‘santé’ à la Réunion

Contexte de la recherche ‘santé’ à la Réunion. Trois axes forts de recherche : Maladies infectieuses (GRI, CHR, CRVOI, CIC-EC, INVS/ARS) Maladies métaboliques (GEICO, CHR, CIC-EC, INVS/ARS) Périnatalité (CHR, CIC-EC, INVS/ARS ).

herman-carter
Download Presentation

Contexte de la recherche ‘santé’ à la Réunion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contexte de la recherche ‘santé’ à la Réunion Trois axes forts de recherche: Maladies infectieuses (GRI, CHR, CRVOI, CIC-EC, INVS/ARS) Maladies métaboliques (GEICO, CHR, CIC-EC, INVS/ARS) Périnatalité (CHR, CIC-EC, INVS/ARS) Pr P Gasque (INSERM U945), directeur du GRI (EA4517) et administrateur provisoire de la recherche hospitalo-universitaire pour l’UFR santé

  2. Fédération Environnement Biodiversité Santé Financements de la recherche: Plan quinquennal (labos + Fed) CPER/FEDER (équipement) PHRC ANR PCRD7: RUNEMERGE ICRES

  3. ICRESTitle:Integration of Chikungunya research Research area:HEALTH.2010.2.3.3-3 Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever. FP7-HEALTH-2010-single-stage Project start date: [2010-12-01] Programme coopération du PCRD7

  4. Participants • STEINBEIS INNOVATION GGMBH GERMANY • UNIVERSITY OF MALAYA MALAYSIA • UNIVERSITE DE LA REUNION FRANCE • BIOMEDICAL SCIENCES INSTITUTES LIMITED BY GUARANTEE SINGAPORE • HELSINGIN YLIOPISTO FINLAND • COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FRANCE • TARTU ULIKOOL ESTONIA • INSTITUT PASTEUR FRANCE • KAROLINSKA INSTITUTET SWEDEN • UNIVERSITAETSKLINIKUM BONN GERMANY • UNIVERSITY OF EDINBURGH, UK (Pr John Fazakerley, Coordinator) In la Reunion: Both scientists (University) and clinicians (hospital) are involved and, hence, bringing fundamental and clinical (translational) research together.

  5. Historique et contexte scientifique • Chikungunya: sous les tropiques et en Europe! INFECTIOUS DISEASES:Chikungunya: No Longer a Third World Disease (Martin Enserink) Science December 2007 INFECTIOUS DISEASES:Massive Outbreak Draws Fresh Attention to Little-Known Virus (Martin Enserink) Science February 2006

  6. World-wide distribution of CHIKV and Ae. albopictus CHIKV (endemic in yellow, imported cases in blue) Ae albopictus (before 1980 in green and after 1980 in pink). Adapted of (Powers and Logue 2007) and of (Charrel, de Lamballerie et al. 2007) Millions of cases worldwide of CHIKV with possible threats for USA

  7. Week 5 in 2006 : over 47 000 cases/week 22 - 28 may 2006 1200 cases/week 2006 1st cases May 2005 450 cases/Week A major epidemic of chikungunya in la Réunion 2005 and 2006 1/3rd of the population was affected Over 270 000 cases

  8. General clinicalpresentation and symptoms INCUBATION: 3-7days ACUTE PHASE: 3-12 days (105-1012 viral RNA/ml blood) Abrupt onset of high fever (over 38°C) 95% symptomatic Rashes Myalgia Polyarthralgia EpidermolysisBullosa Pigmentation Headache Vomiting Exceptional cases: Deaths Hepatitis Cardiopathy Encephalitis Pigmentations 10-20% cases sufferingfromchronicarthritis (RA-like) monthsafter the initial infection (predictive markers: age and initial viral load) (Hoarau et al. J.Immunol 2010)

  9. Chikungunya can cause severe arthritis and encephalitis Arthritogenic Muscle pain CHIKUNGUNYA VIRUS Tenosynovitis (tendon inflammation) 1 Joint arthritis (Swollen knee) 1 Inflammation of the periosteum membrane (Xray) 2 Encephalopathy Encephalitis Perivascular white matter lesions (MRI scan) 3 Hemorrages and cavities 3 Demyelination in subcortical white matter 4 Perivascular lymphocytic infiltrates 4 References: 1 Powers AM. et al. Journal of General Virology, 2007 2 Jaffar-bandjee MC. et al. Microbs and infection, 2009 3 Das T. et al. Progress Neurobiology, 2009 4 Ganesan K. et al. AJNR Am J Neuroradiol , 2008

  10. Objectifs du projet ICRES • Mieux comprendre la physiopathologie du virus chikungunya • Définir l’origine des formes chroniques extrêmement invalidantes • SURTOUT: définir les pistes vaccinales sachant que le vaccin Américain (militaire, lutte contre le bioterrorisme) n’était plus une option

  11. Etapes clefs de notre participation dans ce projet . L’expertise de l’équipe avec des études débutées en 2007 et avec le soutien financier des programmes CPER/FEDER, ANR et PHRC . Constitution de cohortes et études prospectives . Participation dans des réseaux scientifiques sur les maladies infectieuses et donc connaissance des appels Européens . Invitation du coordinateur à la Réunion pour découvrir les équipes et plateaux techniques (CHR, CYROI) 1ère: Participation à Séminaire (Juin 2009, Réunion) avec le début des échanges sur la constitution du réseau 2ème Réunion à Londres, rencontre des autres partenaires et début des opérations de candidature

  12. Différentes étapes de la candidature • Définir la responsabilité d’un sous-programme (Workpackage, WP) • Rédaction du WP en concertation avec les autres membres (2 semaines) • Renseigner les documents administratifs (LEAR, PIC….) • Le coordinateur se charge de rassembler les différents WPs et avec une présentation/synergie cohérente • Novembre 2009 (vacation) finalisation du projet (échanges par emails) • En résumé, procédure aussi simple qu’une demande de financement mais actions de concertation importante entre les membres du consortium (éviter les conflits d’intérêts) FP7 - Legal Entity Appointed Representative

  13. Aspects financiers • Project Acronym:ICRESProject Reference: 261202 Start Date:2010-12-01 Duration: 48 months Project Cost: 4.55 million euro Contract Type: Small or medium-scale focused research project End Date: 2014-11-30 Project Status: Execution Project Funding: 3 million euro (Début à la Réunion: au 1er Mai! Avec du retard)

  14. En conclusion • La masse critique et l’expertise reconnue de l’équipe est importante, participation dans des réseaux • Néanmoins, ne pas hésiter à faire venir les membres d’un consortium en création • Accentuer la visibilité de la recherche Réunionnaise: - Organisation de séminaires, colloques internationaux (ex: IANIS et IBRO school) sur les thématiques phares - Participation aux actions PCRD7 (expertise des dossiers) • Faciliter (surveillance) et accompagner les demandes de financements des équipes: cellule Europe • Être extrêmement réactif

  15. FP7 current ‘Health’ calls: 38

  16. FP7 current ‘Health’ calls: 38

  17. ICRES: Integrated chikungunya research

  18. FP7 current calls Specific information for topic HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. The EU orphan designation will need to be granted at the latest by the stage 2 deadline. Clear indication about the status of designation as an EU orphan drug should nevertheless be provided already for the stage 1 deadline. Identifier: FP7-ERANET-2012-RTD Publication Date: 20 July 2011 Budget: € 38 500 000 Deadline:  28 February 2012 at 17:00:00 (Brussels local time) OJ Reference:OJ C213 of 20 July 2011 Specific Programme(s): COOPERATION Theme(s): Socio-economic sciences and Humanities ; Transport (including Aeronautics) ; General Activities ; Energy ; Health ; Nanosciences, Nanotechnologies, Materials and new Production Technologies - NMP ; Food, Agriculture and Fisheries, and Biotechnology

  19. People Activities • The 'People' Specific Programme will be implemented through actions under five headings: • 'Initial training of researchers to improve mostly young researchers' career perspectives in both public and private sectors, by broadening their scientific and generic skills, including those related to technology transfer and entrepreneurship. • 'Life-long training' to support experienced researchers in complementing or acquiring new skills and competencies or in enhancing inter/multidisciplinarity and/or intersectoral mobility, in resuming a research career after a break and in (re)integrating into a longer term research position in Europe after a trans-national mobility experience. • 'Industry-academia pathways and partnerships' to stimulate intersectoral mobility and increase knowledge sharing through joint research partnerships in longer term co-operation programmes between organisations from academia and industry, in particular SMEs and including traditional manufacturing industries. • 'International dimension', to contribute to the life-long training and career development of EU-researchers, to attract research talent from outside Europe and to foster mutually beneficial research collaboration with research actors from outside Europe. • 'Specific actions' to support removing obstacles to mobility and enhancing the career perspectives of researchers in Europe.

More Related